Suppr超能文献

放射性核素标记纳米羟磷灰石 99mTc:纳米放射性药物构建的新视角。

Radiolabelled nanohydroxyapatite with 99mTc: perspectives to nanoradiopharmaceuticals construction.

机构信息

University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro , Rio de Janeiro , Brazil.

出版信息

Artif Cells Nanomed Biotechnol. 2014 Apr;42(2):88-91. doi: 10.3109/21691401.2013.785954. Epub 2013 Apr 16.

Abstract

The use of nanoparticles is under intense investigation. The possible advantages proposed by these systems are very impressive and the results may be quite schemer. In this scenario, the association of nanoparticles with radioactive materials (radionuclide) may be the most important step since the discovery of radioactive for nuclear medicine and radiopharmacy, especially for cancer targeting and therapy. In this study, we developed radiolabelled nanoparticles of hydroxyapatite with technetium 99m for bone cancer imaging. The results demonstrated that it is possible to label nanoparticles of hydroxyapatite, and due to its physicochemical properties is possible to develop nano-radiopharmaceutical for bone imaging.

摘要

纳米颗粒的应用正受到广泛关注。这些系统所提出的可能的优势令人印象深刻,其结果可能非常有前景。在这种情况下,将纳米颗粒与放射性物质(放射性核素)结合可能是最重要的一步,因为放射性核素的发现开创了核医学和放射性药物学的新纪元,特别是在癌症靶向治疗方面。在这项研究中,我们开发了用锝 99m 标记的羟基磷灰石纳米颗粒,用于骨癌成像。结果表明,标记羟基磷灰石纳米颗粒是可行的,并且由于其物理化学性质,可以开发用于骨成像的纳米放射性药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验